Surprising setback for Lilly

Quote






anonymous said:
It's quite surprising that Eli Lilly's Lartruvo failed in the latest study, despite demonstrating its healing capabilities in the earlier trial. The result must have come as s big disappointment to the oncology team, especially after the ambitious acquisition of Loxo.
Click to expand...

I would put money down on the fact that the writing had been on the walls for years. My experiences at Lilly are that people involved in product launches are more concerned with building their own resumes, than they are about making the right decision. They want to be able to say they launched Lartruvo or were instrumental in its launch. No one cares if your decisions leads to people losing their jobs. It's despicable. Lilly is a joke.
 






Thank you for your insightful critique Mr Science

anonymous said:
I would put money down on the fact that the writing had been on the walls for years. My experiences at Lilly are that people involved in product launches are more concerned with building their own resumes, than they are about making the right decision. They want to be able to say they launched Lartruvo or were instrumental in its launch. No one cares if your decisions leads to people losing their jobs. It's despicable. Lilly is a joke.
Click to expand...
 






















































Top Bottom
Back
Quote